Ponesimod — Membership Pricing

Other medications in Neurological

• Pramipexole
• Promethazine
• Propranolol
• Rasagiline
• Riluzole
• Rimegepant
• Risdiplam
• Rivastigmine

About Ponesimod

Living with multiple sclerosis (MS) presents unique challenges, and effective treatment is paramount. Ponesimod, known by its brand name Ponvory, offers a targeted oral therapy for relapsing forms of MS. At TheDrugClub, we believe essential medications should be accessible and affordable. Multiple Sclerosis (MS) is a chronic, autoimmune disease that affects the brain, spinal cord, and optic nerves, leading to a wide range of symptoms from fatigue and numbness to mobility issues. For adults living with relapsing forms of MS—including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease—finding an effective treatment is crucial for managing symptoms and slowing disease progression. ### What Ponesimod Treats

Ponesimod (brand name Ponvory) is an oral medication specifically approved to treat relapsing forms of multiple sclerosis. It aims

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Ponesimod is approved for (FDA label)

PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: December 4, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ponesimod (FDA label)

PONVORY is available as round, biconvex, film-coated tablets for oral use.

Source: FDA prescribing information (DailyMed). Set ID: 0c025ba8-ba51-272e-e063-6294a90ad120. SPL document ID: 5280b437-62d4-417f-bd65-eb8944a85166. Label effective date: December 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ponesimod (FDA label)

The following serious adverse reactions are described elsewhere in labeling: Infections [see Warnings and Precautions ( 5.1 )] Bradyarrhythmia and Atrioventricular Conduction Delays [see Warnings and Precautions ( 5.2 )] Respiratory Effects [see Warnings and Precautions ( 5.3 )] Liver Injury [see Warnings and Precautions ( 5.4 )] Increased Blood Pressure [see Warnings and Precautions ( 5.5 )] Cutaneous Malignancies [see Warnings and Precautions ( 5.6 )] Fetal Risk [see Warnings and Precautions ( 5.7 )] Macular Edema [see Warnings and Precautions ( 5.8 )] Posterior Reversible Encephalopathy Syndrome [see Warnings and Precautions ( 5.9 )] Unintended Additive Immunosuppressive Effects From Prior Treatment With Immunosuppressive or Immune-Modulating Therapies [see Warnings and Precautions ( 5.10 )] Severe Increase in Disability After Stopping PONVORY [see Warnings and Precautions ( 5.11 )] Immune System Effects After Stopping PONVORY [see Warnings and Precautions ( 5.12 )] Most common adverse reactions (incidence at least 10%) are upper respiratory tract infection, hepatic transaminase elevation, and hypertension. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Vanda Pharmaceuticals, Inc. at 833-933-9331, FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 0c025ba8-ba51-272e-e063-6294a90ad120. SPL document ID: 5280b437-62d4-417f-bd65-eb8944a85166. Label effective date: December 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ponesimod (FDA label)

PONVORY is contraindicated in patients who: In the last 6 months, have experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart failure [see Warnings and Precautions ( 5.2 )] Have presence of Mobitz type II second-degree, third-degree AV block, sick sinus syndrome, or sino-atrial block, unless patient has a functioning pacemaker [see Warnings and Precautions ( 5.2 )] In the last 6 months, experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III/IV heart failure ( 4 ) Presence of Mobitz type II second-degree, third-degree AV block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 0c025ba8-ba51-272e-e063-6294a90ad120. SPL document ID: 5280b437-62d4-417f-bd65-eb8944a85166. Label effective date: December 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ponesimod (FDA label)

Infections : PONVORY may increase the risk of infections. Obtain a complete blood count (CBC) before initiating treatment. Monitor for infection during treatment and for 1-2 weeks after discontinuation. Do not start PONVORY in patients with active infection. ( 5.1 ) Bradyarrhythmia and Atrioventricular Conduction Delays : PONVORY may result in a transient decrease in heart rate; titration is required for treatment initiation. Check an electrocardiogram (ECG) to assess for preexisting cardiac conduction abnormalities before starting PONVORY. Consider cardiology consultation for conduction abnormalities or concomitant use with other drugs that decrease heart rate. ( 5.2 , 7.2 , 7.3 ) Respiratory Effects : May cause a decline in pulmonary function. Assess pulmonary function (e.g., spirometry) if clinically indicated. ( 5.3 ) Liver Injury : Discontinue if significant liver injury is confirmed.

Source: FDA prescribing information (DailyMed). Set ID: 0c025ba8-ba51-272e-e063-6294a90ad120. SPL document ID: 5280b437-62d4-417f-bd65-eb8944a85166. Label effective date: December 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ponesimod (FDA label)

Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. ( 7.4 ) 7.1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration [see Warnings and Precautions ( 5.1 )] . When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system [see Warnings and Precautions ( 5.10 )] . Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended.

Source: FDA prescribing information (DailyMed). Set ID: 0c025ba8-ba51-272e-e063-6294a90ad120. SPL document ID: 5280b437-62d4-417f-bd65-eb8944a85166. Label effective date: December 4, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.